Patents by Inventor Nicholas Valiante

Nicholas Valiante has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190175727
    Abstract: The disclosure features immunomodulatory therapeutic compositions of an mRNA encoding an activating oncogene mutation peptide and an mRNA encoding a polypeptide that enhances immune responses to the activating oncogene mutation peptide, for example an mRNA encoding an immune potentiator. The disclosure also features methods of using the same, for example, to stimulate anti-cancer immune responses.
    Type: Application
    Filed: February 19, 2019
    Publication date: June 13, 2019
    Inventors: Eric Yi-Chun HUANG, Sze-Wah TSE, Jared IACOVELLI, Kristine MCKINNEY, Nicholas VALIANTE
  • Publication number: 20190008938
    Abstract: The invention relates to concatemeric peptide epitope RNAs, as well as methods and compositions thereof. mRNA vaccines are also provided according to the invention, including cancer vaccines.
    Type: Application
    Filed: July 29, 2016
    Publication date: January 10, 2019
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Nicholas Valiante, Tal Zaks
  • Publication number: 20180318409
    Abstract: The disclosure relates to cancer ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: October 21, 2016
    Publication date: November 8, 2018
    Applicant: ModernaTX, Inc.
    Inventors: Nicholas Valiante, Tal Zaks, Eric Yi-Chun Huang, Giuseppe Ciaramella
  • Publication number: 20160310590
    Abstract: Adjuvant compositions comprising type 1 interferon inducers, such as double-stranded RNA, in combination with antigen delivery systems and/or immunostimulatory molecules, such as immunostimulatory nucleic acid sequences, for enhancing the immune response of a coadministered antigen, are described.
    Type: Application
    Filed: July 5, 2016
    Publication date: October 27, 2016
    Inventors: Derek O'Hagan, Nicholas Valiante
  • Patent number: 8895577
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X3 is N; X4 is N Or CR3; X5 is —CR4?CR5.
    Type: Grant
    Filed: April 22, 2013
    Date of Patent: November 25, 2014
    Inventors: Tom Yao-Hsiang Wu, Yongkai Li, Alex Cortez, Yefen Zou, Pranab Mishra, Xiaoyue Zhang, Nicholas Valiante
  • Publication number: 20140161887
    Abstract: Adjuvant compositions comprising type 1 interferon inducers, such as double-stranded RNA, in combination with antigen delivery systems and/or immunostimulatory molecules, such as immunostimulatory nucleic acid sequences, for enhancing the immune response of a coadministered antigen, are described.
    Type: Application
    Filed: November 15, 2013
    Publication date: June 12, 2014
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Derek O'Hagan, Nicholas Valiante
  • Publication number: 20130253002
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X3 is N; X4 is N Or CR3; X5 is —CR4?CR5.
    Type: Application
    Filed: April 22, 2013
    Publication date: September 26, 2013
    Inventors: TOM YAO-HSIANG WU, YONGKAI LI, ALEX CORTEZ, YEFEN ZOU, PRANAB MISHRA, XIAOYUE ZHANG, NICHOLAS VALIANTE
  • Patent number: 8466167
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X3 is N; X4 is N Or CR3; X5 is —CR4?CR5.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: June 18, 2013
    Assignees: IRM LLC, Novartis AG
    Inventors: Tom Yao Hsiang Wu, Yongkai Li, Alex Cortez, Yefen Zou, Pranab Mishra, Xiaoyue Zhang, David Skibinski, Manmohan Singh, Nicholas Valiante
  • Publication number: 20130101622
    Abstract: The invention provides novel compositions comprising imidazoquinoxaline compounds of formula (I) and analogs thereof. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an) other agent(s).
    Type: Application
    Filed: May 7, 2012
    Publication date: April 25, 2013
    Applicant: Novartis AG
    Inventors: James SUTTON, Feng Xu, Nicholas Valiante, Jiong Lan
  • Publication number: 20130096103
    Abstract: The invention provides novel compositions comprising imidazoquinoline compounds. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an)other agent(s).
    Type: Application
    Filed: June 19, 2012
    Publication date: April 18, 2013
    Applicant: NOVARTIS VACCINES & DIAGNOSTICS, INC.
    Inventors: Nicholas VALIANTE, Feng Xu, Xiaodong Lin, Daniel Chu, Xiaojing Michael Wang
  • Patent number: 8173657
    Abstract: The invention provides novel compositions comprising imidazoquinoxaline compounds of formula (I) and analogs thereof. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an) other agent(s).
    Type: Grant
    Filed: March 23, 2007
    Date of Patent: May 8, 2012
    Assignee: Novartis AG
    Inventors: James Sutton, Feng Xu, Nicholas Valiante, Jiong Lan
  • Patent number: 8165823
    Abstract: A method for identifying a polypeptide which acts as an adjuvant in a host organism. The invention further provides adjuvant compositions comprising said polypeptides and optionally further comprising an antigen.
    Type: Grant
    Filed: July 15, 2006
    Date of Patent: April 24, 2012
    Assignee: Novartis AG
    Inventors: Jeffrey Ulmer, Nicholas Valiante, Feng Xu, Claudio Donati, Antonello Covacci
  • Patent number: 8063063
    Abstract: The invention provides novel compositions comprising Imidazopyridine compounds. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an)other agent(s).
    Type: Grant
    Filed: March 23, 2007
    Date of Patent: November 22, 2011
    Assignee: Novartis AG
    Inventors: James Sutton, Nicholas Valiante
  • Publication number: 20110217323
    Abstract: The invention provides novel compositions comprising imidazoquinoline compounds. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an) other agent(s).
    Type: Application
    Filed: May 16, 2011
    Publication date: September 8, 2011
    Applicant: NOVARTIS VACCINES & DIAGNOSTICS, INC.
    Inventors: Nicholas VALIANTE, Feng Xu, Xiaodong Lin, Daniel Chu, Xiaojing Michael Wang
  • Patent number: 7994283
    Abstract: A dimeric protein comprising a first fusion protein and a second fusion protein, wherein the first fusion protein comprises a targeting domain, a leucine zipper domain, and an antigen; and wherein the second fusion protein comprises a targeting domain, a leucine zipper domain, and optionally an antigen. Nucleic acid vectors encoding proteins of the invention are provided, particularly for use in nucleic acid vaccination.
    Type: Grant
    Filed: June 1, 2009
    Date of Patent: August 9, 2011
    Assignee: Novartis Vaccines and Diagnostics SRL
    Inventor: Nicholas Valiante
  • Publication number: 20110104186
    Abstract: The invention provides immunostimulatory compositions comprising a small molecule immuno-potentiator (SMIP) compound and methods of administration thereof. Also provided are methods of administering a SMIP compound in an effective amount to enhance the immune response of a subject to an antigen. Further provided are novel compositions and methods of administering SMIP compounds alone or in combination with another agent for the treatment of cancer, infectious diseases and/or allergies/asthma. In a further aspect, the invention relates generally to methods of screening for small molecule immuno-modulatory compositions.
    Type: Application
    Filed: June 24, 2005
    Publication date: May 5, 2011
    Inventors: Nicholas Valiante, Feng Xu, Johanna Jansen, Susan Kaufman
  • Publication number: 20110081365
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X3 is N; X4 is N Or CR3; X5 is —CR4?CR5.
    Type: Application
    Filed: February 27, 2009
    Publication date: April 7, 2011
    Applicants: IRM LLC, Novartis 35
    Inventors: Alex Cortez, Yongkai Li, Pranab Mishra, Manmohan Singh, David Skibinski, Nicholas Valiante, Tom Yao-Hsiang Wu, Xiaoyue Zhang, Yefen Zou
  • Patent number: 7838015
    Abstract: A combination of CpG oligonucleotides and polymer microparticles is an extremely effective adjuvant for Neisserial antigens. The invention therefore provides a composition comprising: (a) a Neisserial antigen; (b) a CpG oligonucleotide; and (c) a biodegradable polymer microparticle.
    Type: Grant
    Filed: October 3, 2002
    Date of Patent: November 23, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Derek O'Hagan, Nicholas Valiante
  • Publication number: 20100226931
    Abstract: Methods of stimulating an immune response and treating patients responsive thereto with 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-diones, staurosporine analogs, derivatized pyridazines, chromen-4-ones, indolinones, quinazolines, nucleoside analogs, and other small molecules are disclosed. In a preferred embodiment benzopyrimidine derivatives such as ZD-6474, MLN-518, lapatinib, gefitinib or erlotinib are used.
    Type: Application
    Filed: June 24, 2005
    Publication date: September 9, 2010
    Inventors: Nicholas Valiante, Feng Xu, Joel B. Silver
  • Patent number: RE45137
    Abstract: A combination of CpG oligonucleotides and polymer microparticles is an extremely effective adjuvant for Neisserial antigens. The invention therefore provides a composition comprising: (a) a Neisserial antigen; (b) a CpG oligonucleotide; and (c) a biodegradable polymer microparticle.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: September 16, 2014
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Derek O'Hagan, Nicholas Valiante